The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...
The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities ...
The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...
Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at the Department of Health and Human ...
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to ...
AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for ...
The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on ...
The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the ...
On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...
Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results